文献速递肾血管病与高血压慢性肾脏病

难治性高血压的识别与管理

Recognition and Management of Resistant Hypertension.
PubMed 文献 · Clin J Am Soc Nephrol · 2016-11-28

本文针对难治性高血压的识别与管理提出系统框架,指出30%-60%高血压患者未达血压目标,CKD患者常为难治性高血压且被排除于降压试验之外。作者提出统一定义、标准化阶梯评估、继发性病因筛查,并讨论伴或不伴CKD患者的循证管理差异及新兴疗法定位。

要点

  • 难治性高血压定义为诊室与诊室外血压均确认超标且已用至少三种降压药(含利尿剂)优化剂量治疗。
  • 每位患者应接受标准化阶梯评估,评估饮食生活方式与药物依从性并停用可能加重高血压的物质。
  • 临床高度怀疑者应筛查继发性高血压病因,CKD患者管理需考虑利尿剂与盐皮质激素受体拮抗剂角色差异。

核心结论

  • 作者支持采用系统性方法改善这一未来肾脏与心血管事件高危脆弱患者群体的识别与照护。

研究设计与样本

  • 本文为综述,围绕难治性高血压的识别与管理进行讨论,未报告检索范围。

主要发现

  • 尽管高血压知晓与治疗改善,30%-60%高血压患者未达血压目标并持续面临靶器官损害风险。
  • CKD患者常存在难治性高血压,但CKD患者历史上被排除于高血压治疗试验之外,最佳治疗数据有限。

关键数值与推荐

  • 作者提出难治性高血压定义为诊室与诊室外测量均确认血压超过适宜目标,同时患者正接受至少三种降压药(包括利尿剂)且剂量优化至无不可耐受副作用下获益最大。
  • 作者推荐每位患者接受标准化阶梯评估,评估饮食生活方式与降压药依从性,识别并减少障碍,停用可能加重高血压的物质。
  • 临床高度怀疑者应评估高血压潜在继发性病因。

临床怎么用

  • 作者建议对难治性高血压采用标准化阶梯评估与继发性病因筛查,并讨论伴或不伴CKD患者的循证管理差异。
  • 作者讨论利尿剂与盐皮质激素受体拮抗剂的具体角色以及肾去神经与压力感受器刺激等新兴疗法的当前定位。

局限性

  • CKD合并难治性高血压患者的最佳治疗数据有限,因为CKD患者历史上被排除于高血压治疗试验之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite improvements in hypertension awareness and treatment, 30%-60% of hypertensive patients do not achieve BP targets and subsequently remain at risk for target organ damage. This therapeutic gap is particularly important to nephrologists, who frequently encounter treatment-resistant hypertension in patients with CKD. Data are limited on how best to treat patients with CKD and resistant hypertension, because patients with CKD have historically been excluded from hypertension treatment trials. First, we propose a consistent definition of resistant hypertension as BP levels confirmed by both in-office and out-of-office measurements that exceed appropriate targets while the patient is receiving treatment with at least three antihypertensive medications, including a diuretic, at dosages optimized to provide maximum benefit in the absence of intolerable side effects. Second, we recommend that each patient undergo a standardized, stepwise evaluation to assess adherence to dietary and lifestyle modifications and antihypertensive medications to identify and reduce barriers and discontinue use of substances that may exacerbate hypertension. Patients in whom there is high clinical suspicion should be evaluated for potential secondary causes of hypertension. Evidence-based management of resistant hypertension is discussed with special considerations of the differences in approach to patients with and without CKD, including the specific roles of diuretics and mineralocorticoid receptor antagonists and the current place of emerging therapies, such as renal denervation and baroreceptor stimulation. We endorse use of such a systematic approach to improve recognition and care for this vulnerable patient group that is at high risk for future kidney and cardiovascular events.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Braam B, Taler SJ, Rahman M, et al. Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol. 2016. PMID: 27895136. doi:10.2215/CJN.06180616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。